Skip to main content

Akebia Therapeutics: Q1 Earnings Snapshot

CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Akebia Therapeutics Inc. (AKBA) on Thursday reported a first-quarter loss of $9.1 million, after reporting a profit in the same period a year earlier.

The Cambridge, Massachusetts-based company said it had a loss of 3 cents per share.

The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 1 cent per share.

The kidney disease treatment developer posted revenue of $53.5 million in the period, which also missed Street forecasts. Three analysts surveyed by Zacks expected $56.5 million.

The company’s shares closed at $1.49. A year ago, they were trading at $2.32.

_____

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on AKBA at https://www.zacks.com/ap/AKBA

One Tech Tip: What to know about flying with lithium ion portable battery chargers

Jetting off soon for summer travels? If you're planning on bringing an extra battery charger for your phone or other devices, be aware of the latest rules when taking one on a flight. Rechargeable lithium-ion portable battery chargers, also known as power banks, come in protective enclosures of various shapes and sizes. They're a handy and popular way for getting more juice when you're on the move. But after a spate of smoke or fire incidents, U.S. and international aviation authorities have issued new guidelines and airlines have tightened up rules for passengers. Here's a guide on flying with power banks.
Read Next Story